RxDoctor Payments Data

Michael McAvoy, MD

Allergy · Saginaw, MINPI 1700863859

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $487 of the $807 with a category attached, or 60.3%. It is spread thinly across 10 manufacturers, the largest accounting for just 19.9%. That places this record below the midpoint for allergy clinicians in MI, where the typical reported total is $2,352.

$807in general payments, 2019–2025

Across 22 payments — averaging $36.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$161
  • Genentech USA, Inc.$149
  • Sanofi-aventis U.S. LLC$147
  • Regeneron Healthcare Solutions, Inc.$117
  • Takeda Pharmaceuticals U.S.A., Inc.$112
  • Pfizer$35
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$48760%
  • Education$32040%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$807 in reported general payments places this provider in the 40th percentile of 22 allergy providers in Michigan.

See all allergy providers in Michigan

Medicare billing

Part B allowed, 2024
$69,058
Medicare patients
204
Services billed
4,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo12$626,321
Trelegy ElliptaFluticasone/Umeclidin/Vilanter181$220,449
XolairOmalizumab74$205,856
Dupixent SyringeDupilumab45$193,279
Dupixent PenDupilumab38$162,450
Fasenra PenBenralizumab13$70,676
Advair HfaFluticasone Propion/Salmeterol73$51,938
Fluticasone-SalmeterolFluticasone Propion/Salmeterol154$40,412
Breo ElliptaFluticasone/Vilanterol37$34,475
Spiriva RespimatTiotropium Bromide23$21,281
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate42$20,186
Qvar RedihalerBeclomethasone Dipropionate30$14,643
Pulmicort FlexhalerBudesonide28$14,020
SymbicortBudesonide/Formoterol Fumarate36$13,459
Epinephrine50$13,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$112$626,32112 claims
GSKTrelegy Ellipta, Breo Ellipta$13$254,924218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 22 allergy providers in Michigan.

Other allergy in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →